TherapeuticsMD Inc TXMD 0.39% shares are down another 7.0 percent on Tuesday after a 19.4 percent drop Monday on news that the company received a letter from the U.S. Food and Drug Administration noting “deficiencies” in the company’s TX-004 drug candidate. TX-004 is an estrogen vaginal soft gel capsule used for the treatment of severe dyspareunia resulting from Vulvar Vaginal Atrophy.
Market Reactions; Voices From The Street
While the company itself is still not completely clear on the specific deficiencies the FDA mentions in the letter, the market has certainly assumed the worst, sending shares of TherapeuticsMD down 28.7 percent in three days.
However, Jefferies analyst Matthew Andrews says traders shouldn’t rush to judgment. According to Andrews, the company has indicated that the FDA concerns may not be a big deal.
“In our call with the company, TXMD characterized FDA dialog through the ‘004 review cycle as ‘benign’ discussions, possibly suggesting the deficiencies may be minor in nature,” Andrews explained.
TherapeuticsMD is currently in the process of setting up a meeting with FDA officials to gain some clarity on the issues.
Surprise Letter, But Why?
Andrews said the FDA letter was likely a complete surprise to company management. A Jefferies consultant with a background at the FDA indicated four theoretical justifications for such a late-stage issue:
- Documentation errors relating to clinical data quality.
- Longer-term safety data from REJOICE could have raised red flags.
- Concerns about the drug’s long-term shelf-life stability.
- An issue with chemistry, manufacturing and controls (CMC).
Until the company provides an update, Jefferies remains…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
